APO Research
Talk to an analyst

APO RESEARCH · REPORT

AI Clinical Endpoint Assessment Software

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global AI Clinical Endpoint Assessment Software Market Outlook and Growth Opportunities 2026

12 August 2026210 pages

Choose your research edition.

Industry ResearchAI Clinical Endpoint Assessment Software Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal AI Clinical Endpoint Assessment Software Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal AI Clinical Endpoint Assessment Software Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal AI Clinical Endpoint Assessment Software Market Outlook and Growth Opportunities 2026210 pages · $4,250 USDMarket Analysis & ForecastGlobal AI Clinical Endpoint Assessment Software Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global AI Clinical Endpoint Assessment Software market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for AI Clinical Endpoint Assessment Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for AI Clinical Endpoint Assessment Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for AI Clinical Endpoint Assessment Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the AI Clinical Endpoint Assessment Software market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the AI Clinical Endpoint Assessment Software market include IQVIA, ICON, Perceptive, Clinical Ink, Koneksa, AiCure, Medable, PathAI and Proscia, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global AI Clinical Endpoint Assessment Software market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of AI Clinical Endpoint Assessment Software and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents AI Clinical Endpoint Assessment Software revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global AI Clinical Endpoint Assessment Software market.

AI Clinical Endpoint Assessment Software Segment by Company

IQVIA

ICON

Perceptive

Clinical Ink

Koneksa

AiCure

Medable

PathAI

Proscia

Paige

IXICO

Median Technologies

VIDA Diagnostics

Image Analysis Group

QMENTA

Cambridge Cognition

Cogstate

Empatica

Cumulus Neuroscience

Rune Labs

VivoSense

NeuraLight

Aural Analytics

Linus Health

Quibim

Perspectum

Brainomix

Taimei Technology

UnionClin

XincereMed

Clario

Medidata

Signant Health

AI Clinical Endpoint Assessment Software Segment by Type

Medical Imaging Endpoints

Digital Pathology Endpoints

Electronic Clinical Outcome Assessment

Wearable and Physiological Endpoints

Voice, Video and Cognitive Endpoints

Multimodal Endpoints

AI Clinical Endpoint Assessment Software Segment by Application

Oncology

Neurology and Psychiatry

Cardiovascular and Metabolic Diseases

Respiratory Diseases

Musculoskeletal and Immunology

Other Therapeutic Areas

AI Clinical Endpoint Assessment Software Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global AI Clinical Endpoint Assessment Software status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the AI Clinical Endpoint Assessment Software key companies, revenue, market share, and recent developments.

3. To split the AI Clinical Endpoint Assessment Software breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions AI Clinical Endpoint Assessment Software market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify AI Clinical Endpoint Assessment Software significant trends, drivers, influence factors in global and regions.

6. To analyze AI Clinical Endpoint Assessment Software competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI Clinical Endpoint Assessment Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of AI Clinical Endpoint Assessment Software and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI Clinical Endpoint Assessment Software.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global AI Clinical Endpoint Assessment Software industry.

Chapter 3: Detailed analysis of AI Clinical Endpoint Assessment Software company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of AI Clinical Endpoint Assessment Software in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of AI Clinical Endpoint Assessment Software in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. AI Clinical Endpoint Assessment Software Industry Trends Table 2. AI Clinical Endpoint Assessment Software Industry Drivers Table 3. AI Clinical Endpoint Assessment Software Industry Opportunities and Challenges Table 4. AI Clinical Endpoint Assessment Software Industry Restraints Table 5. Global AI Clinical Endpoint Assessment Software Revenue by Company (US$ Million) & (2021-2026) Table 6. Global AI Clinical Endpoint Assessment Software Revenue Share by Company (2021-2026) Table 7. Global AI Clinical Endpoint Assessment Software Company Ranking, (2024-2026) & (US$ Million) Table 8. Global AI Clinical Endpoint Assessment Software Key Company Manufacturing Base & Headquarters Table 9. Global AI Clinical Endpoint Assessment Software Company, Product Type & Application Table 10. Global AI Clinical Endpoint Assessment Software Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global AI Clinical Endpoint Assessment Software by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Medical Imaging Endpoints Table 15. Significant Companies of Digital Pathology Endpoints Table 16. Significant Companies of Electronic Clinical Outcome Assessment Table 17. Significant Companies of Wearable and Physiological Endpoints Table 18. Significant Companies of Voice, Video and Cognitive Endpoints Table 19. Significant Companies of Multimodal Endpoints Table 20. Global AI Clinical Endpoint Assessment Software Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global AI Clinical Endpoint Assessment Software Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global AI Clinical Endpoint Assessment Software Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global AI Clinical Endpoint Assessment Software Sales Value Share by Type (2021-2026) Table 24. Global AI Clinical Endpoint Assessment Software Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Oncology Table 26. Significant Companies of Neurology and Psychiatry Table 27. Significant Companies of Cardiovascular and Metabolic Diseases Table 28. Significant Companies of Respiratory Diseases Table 29. Significant Companies of Musculoskeletal and Immunology Table 30. Significant Companies of Other Therapeutic Areas Table 31. Global AI Clinical Endpoint Assessment Software Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global AI Clinical Endpoint Assessment Software Sales Value by Application (2021-2026) & (US$ Million) Table 33. Global AI Clinical Endpoint Assessment Software Sales Value by Application (2027-2032) & (US$ Million) Table 34. Global AI Clinical Endpoint Assessment Software Sales Value Share by Application (2021-2026) Table 35. Global AI Clinical Endpoint Assessment Software Sales Value Share by Application (2027-2032) Table 36. Global AI Clinical Endpoint Assessment Software Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global AI Clinical Endpoint Assessment Software Sales Value by Region (2021-2026) & (US$ Million) Table 38. Global AI Clinical Endpoint Assessment Software Sales Value Share by Region (2021-2026) Table 39. Global AI Clinical Endpoint Assessment Software Sales Value by Region (2027-2032) & (US$ Million) Table 40. Global AI Clinical Endpoint Assessment Software Sales Value Share by Region (2027-2032) Table 41. Global AI Clinical Endpoint Assessment Software Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global AI Clinical Endpoint Assessment Software Sales Value by Country (2021-2026) & (US$ Million) Table 43. Global AI Clinical Endpoint Assessment Software Sales Value Market Share by Country (2021-2026) Table 44. Global AI Clinical Endpoint Assessment Software Sales Value by Country (2027-2032) & (US$ Million) Table 45. Global AI Clinical Endpoint Assessment Software Sales Value Market Share by Country (2027-2032) Table 46. IQVIA Company Information Table 47. IQVIA Business Overview Table 48. IQVIA AI Clinical Endpoint Assessment Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. IQVIA AI Clinical Endpoint Assessment Software Product Portfolio Table 50. IQVIA Recent Development Table 51. ICON Company Information Table 52. ICON Business Overview Table 53. ICON AI Clinical Endpoint Assessment Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. ICON AI Clinical Endpoint Assessment Software Product Portfolio Table 55. ICON Recent Development Table 56. Perceptive Company Information Table 57. Perceptive Business Overview Table 58. Perceptive AI Clinical Endpoint Assessment Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Perceptive AI Clinical Endpoint Assessment Software Product Portfolio Table 60. Perceptive Recent Development Table 61. Clinical Ink Company Information Table 62. Clinical Ink Business Overview Table 63. Clinical Ink AI Clinical Endpoint Assessment Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Clinical Ink AI Clinical Endpoint Assessment Software Product Portfolio Table 65. Clinical Ink Recent Development Table 66. Koneksa Company Information Table 67. Koneksa Business Overview Table 68. Koneksa AI Clinical Endpoint Assessment Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Koneksa AI Clinical Endpoint Assessment Software Product Portfolio Table 70. Koneksa Recent Development Table 71. AiCure Company Information Table 72. AiCure Business Overview Table 73. AiCure AI Clinical Endpoint Assessment Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. AiCure AI Clinical Endpoint Assessment Software Product Portfolio Table 75. AiCure Recent Development Table 76. Medable Company Information Table 77. Medable Business Overview Table 78. Medable AI Clinical Endpoint Assessment Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Medable AI Clinical Endpoint Assessment Software Product Portfolio Table 80. Medable Recent Development Table 81. PathAI Company Information Table 82. PathAI Business Overview Table 83. PathAI AI Clinical Endpoint Assessment Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. PathAI AI Clinical Endpoint Assessment Software Product Portfolio Table 85. PathAI Recent Development Table 86. Proscia Company Information Table 87. Proscia Business Overview Table 88. Proscia AI Clinical Endpoint Assessment Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Proscia AI Clinical Endpoint Assessment Software Product Portfolio Table 90. Proscia Recent Development Table 91. Paige Company Information Table 92. Paige Business Overview Table 93. Paige AI Clinical Endpoint Assessment Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Paige AI Clinical Endpoint Assessment Software Product Portfolio Table 95. Paige Recent Development Table 96. IXICO Company Information Table 97. IXICO Business Overview Table 98. IXICO AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. IXICO AI Clinical Endpoint Assessment Software Product Portfolio Table 100. IXICO Recent Development Table 101. Median Technologies Company Information Table 102. Median Technologies Business Overview Table 103. Median Technologies AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Median Technologies AI Clinical Endpoint Assessment Software Product Portfolio Table 105. Median Technologies Recent Development Table 106. VIDA Diagnostics Company Information Table 107. VIDA Diagnostics Business Overview Table 108. VIDA Diagnostics AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. VIDA Diagnostics AI Clinical Endpoint Assessment Software Product Portfolio Table 110. VIDA Diagnostics Recent Development Table 111. Image Analysis Group Company Information Table 112. Image Analysis Group Business Overview Table 113. Image Analysis Group AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Image Analysis Group AI Clinical Endpoint Assessment Software Product Portfolio Table 115. Image Analysis Group Recent Development Table 116. QMENTA Company Information Table 117. QMENTA Business Overview Table 118. QMENTA AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. QMENTA AI Clinical Endpoint Assessment Software Product Portfolio Table 120. QMENTA Recent Development Table 121. Cambridge Cognition Company Information Table 122. Cambridge Cognition Business Overview Table 123. Cambridge Cognition AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Cambridge Cognition AI Clinical Endpoint Assessment Software Product Portfolio Table 125. Cambridge Cognition Recent Development Table 126. Cogstate Company Information Table 127. Cogstate Business Overview Table 128. Cogstate AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Cogstate AI Clinical Endpoint Assessment Software Product Portfolio Table 130. Cogstate Recent Development Table 131. Empatica Company Information Table 132. Empatica Business Overview Table 133. Empatica AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Empatica AI Clinical Endpoint Assessment Software Product Portfolio Table 135. Empatica Recent Development Table 136. Cumulus Neuroscience Company Information Table 137. Cumulus Neuroscience Business Overview Table 138. Cumulus Neuroscience AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. Cumulus Neuroscience AI Clinical Endpoint Assessment Software Product Portfolio Table 140. Cumulus Neuroscience Recent Development Table 141. Rune Labs Company Information Table 142. Rune Labs Business Overview Table 143. Rune Labs AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 144. Rune Labs AI Clinical Endpoint Assessment Software Product Portfolio Table 145. Rune Labs Recent Development Table 146. VivoSense Company Information Table 147. VivoSense Business Overview Table 148. VivoSense AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 149. VivoSense AI Clinical Endpoint Assessment Software Product Portfolio Table 150. VivoSense Recent Development Table 151. NeuraLight Company Information Table 152. NeuraLight Business Overview Table 153. NeuraLight AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 154. NeuraLight AI Clinical Endpoint Assessment Software Product Portfolio Table 155. NeuraLight Recent Development Table 156. Aural Analytics Company Information Table 157. Aural Analytics Business Overview Table 158. Aural Analytics AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 159. Aural Analytics AI Clinical Endpoint Assessment Software Product Portfolio Table 160. Aural Analytics Recent Development Table 161. Linus Health Company Information Table 162. Linus Health Business Overview Table 163. Linus Health AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 164. Linus Health AI Clinical Endpoint Assessment Software Product Portfolio Table 165. Linus Health Recent Development Table 166. Quibim Company Information Table 167. Quibim Business Overview Table 168. Quibim AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 169. Quibim AI Clinical Endpoint Assessment Software Product Portfolio Table 170. Quibim Recent Development Table 171. Perspectum Company Information Table 172. Perspectum Business Overview Table 173. Perspectum AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 174. Perspectum AI Clinical Endpoint Assessment Software Product Portfolio Table 175. Perspectum Recent Development Table 176. Brainomix Company Information Table 177. Brainomix Business Overview Table 178. Brainomix AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 179. Brainomix AI Clinical Endpoint Assessment Software Product Portfolio Table 180. Brainomix Recent Development Table 181. Taimei Technology Company Information Table 182. Taimei Technology Business Overview Table 183. Taimei Technology AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 184. Taimei Technology AI Clinical Endpoint Assessment Software Product Portfolio Table 185. Taimei Technology Recent Development Table 186. UnionClin Company Information Table 187. UnionClin Business Overview Table 188. UnionClin AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 189. UnionClin AI Clinical Endpoint Assessment Software Product Portfolio Table 190. UnionClin Recent Development Table 191. XincereMed Company Information Table 192. XincereMed Business Overview Table 193. XincereMed AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 194. XincereMed AI Clinical Endpoint Assessment Software Product Portfolio Table 195. XincereMed Recent Development Table 196. Clario Company Information Table 197. Clario Business Overview Table 198. Clario AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 199. Clario AI Clinical Endpoint Assessment Software Product Portfolio Table 200. Clario Recent Development Table 201. Medidata Company Information Table 202. Medidata Business Overview Table 203. Medidata AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 204. Medidata AI Clinical Endpoint Assessment Software Product Portfolio Table 205. Medidata Recent Development Table 206. Signant Health Company Information Table 207. Signant Health Business Overview Table 208. Signant Health AI Clinical Endpoint Assessment Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 209. Signant Health AI Clinical Endpoint Assessment Software Product Portfolio Table 210. Signant Health Recent Development Table 211. Research Programs/Design for This Report Table 212. Authors List of This Report Table 213. Secondary Sources Table 214. Primary Sources List of Figures Figure 1. AI Clinical Endpoint Assessment Software Product Image Figure 2. Global AI Clinical Endpoint Assessment Software Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global AI Clinical Endpoint Assessment Software Market Size (2021-2032) & (US$ Million) Figure 4. Global AI Clinical Endpoint Assessment Software Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Medical Imaging Endpoints Image Figure 8. Digital Pathology Endpoints Image Figure 9. Electronic Clinical Outcome Assessment Image Figure 10. Wearable and Physiological Endpoints Image Figure 11. Voice, Video and Cognitive Endpoints Image Figure 12. Multimodal Endpoints Image Figure 13. Global AI Clinical Endpoint Assessment Software Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global AI Clinical Endpoint Assessment Software Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global AI Clinical Endpoint Assessment Software Sales Value Share by Type (2021-2032) Figure 16. Oncology Image Figure 17. Neurology and Psychiatry Image Figure 18. Cardiovascular and Metabolic Diseases Image Figure 19. Respiratory Diseases Image Figure 20. Musculoskeletal and Immunology Image Figure 21. Other Therapeutic Areas Image Figure 22. Global AI Clinical Endpoint Assessment Software Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global AI Clinical Endpoint Assessment Software Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global AI Clinical Endpoint Assessment Software Sales Value Share by Application (2021-2032) Figure 25. Global AI Clinical Endpoint Assessment Software Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 26. Global AI Clinical Endpoint Assessment Software Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 27. North America AI Clinical Endpoint Assessment Software Sales Value (2021-2032) & (US$ Million) Figure 28. North America AI Clinical Endpoint Assessment Software Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Europe AI Clinical Endpoint Assessment Software Sales Value (2021-2032) & (US$ Million) Figure 30. Europe AI Clinical Endpoint Assessment Software Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Asia-Pacific AI Clinical Endpoint Assessment Software Sales Value (2021-2032) & (US$ Million) Figure 32. Asia-Pacific AI Clinical Endpoint Assessment Software Sales Value Share by Country (%), 2025 VS 2032 Figure 33. South America AI Clinical Endpoint Assessment Software Sales Value (2021-2032) & (US$ Million) Figure 34. South America AI Clinical Endpoint Assessment Software Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Middle East & Africa AI Clinical Endpoint Assessment Software Sales Value (2021-2032) & (US$ Million) Figure 36. Middle East & Africa AI Clinical Endpoint Assessment Software Sales Value Share by Country (%), 2025 VS 2032 Figure 37. USA AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. USA AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. USA AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Canada AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Canada AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Canada AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Mexico AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Mexico AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Mexico AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Germany AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Germany AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Germany AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. France AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. France AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. France AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. U.K. AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. U.K. AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. U.K. AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Italy AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Italy AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Italy AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Spain AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Spain AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Spain AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Russia AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Russia AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Russia AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Netherlands AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Netherlands AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Netherlands AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Nordic Countries AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Nordic Countries AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Nordic Countries AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. China AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. China AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. China AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Japan AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Japan AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Japan AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. South Korea AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. South Korea AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. South Korea AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. India AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. India AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. India AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Australia AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Australia AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Australia AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Southeast Asia AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Southeast Asia AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Southeast Asia AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Brazil AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Brazil AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Brazil AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Argentina AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Argentina AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Argentina AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Chile AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Chile AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Chile AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Colombia AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Colombia AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Colombia AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Peru AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Peru AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Peru AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Saudi Arabia AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Saudi Arabia AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Saudi Arabia AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Israel AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Israel AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Israel AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. UAE AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. UAE AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. UAE AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Turkey AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Turkey AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Turkey AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Iran AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Iran AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Iran AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Egypt AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Egypt AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Egypt AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Years Considered Figure 122. Research Process Figure 123. Key Executives Interviewed

Scope & coverage.

Types
  • Medical Imaging Endpoints
  • Digital Pathology Endpoints
  • Electronic Clinical Outcome Assessment
  • Wearable and Physiological Endpoints
  • Voice, Video and Cognitive Endpoints
  • Multimodal Endpoints
Applications
  • Oncology
  • Neurology and Psychiatry
  • Cardiovascular and Metabolic Diseases
  • Respiratory Diseases
  • Musculoskeletal and Immunology
  • Other Therapeutic Areas
Companies covered
  • IQVIA
  • ICON
  • Perceptive
  • Clinical Ink
  • Koneksa
  • AiCure
  • Medable
  • PathAI
  • Proscia
  • Paige
  • IXICO
  • Median Technologies
  • VIDA Diagnostics
  • Image Analysis Group
  • QMENTA
  • Cambridge Cognition
  • Cogstate
  • Empatica
  • Cumulus Neuroscience
  • Rune Labs
  • VivoSense
  • NeuraLight
  • Aural Analytics
  • Linus Health
  • Quibim
  • Perspectum
  • Brainomix
  • Taimei Technology
  • UnionClin
  • XincereMed
  • Clario
  • Medidata
  • Signant Health

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global AI Clinical Endpoint Assessment Software Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global AI Clinical Endpoint Assessment Software Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 AI Clinical Endpoint Assessment Software Market Dynamics
  1. 2.1 AI Clinical Endpoint Assessment Software Industry Trends
  2. 2.2 AI Clinical Endpoint Assessment Software Industry Drivers
  3. 2.3 AI Clinical Endpoint Assessment Software Industry Opportunities and Challenges
  4. 2.4 AI Clinical Endpoint Assessment Software Industry Restraints
3 AI Clinical Endpoint Assessment Software Market by Company
  1. 3.1 Global AI Clinical Endpoint Assessment Software Company Revenue Ranking in 2025
  2. 3.2 Global AI Clinical Endpoint Assessment Software Revenue by Company (2021-2026)
  3. 3.3 Global AI Clinical Endpoint Assessment Software Company Ranking (2024-2026)
  4. 3.4 Global AI Clinical Endpoint Assessment Software Company Manufacturing Base and Headquarters
  5. 3.5 Global AI Clinical Endpoint Assessment Software Company Product Type and Application
  6. 3.6 Global AI Clinical Endpoint Assessment Software Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global AI Clinical Endpoint Assessment Software Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 AI Clinical Endpoint Assessment Software Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 AI Clinical Endpoint Assessment Software Market by Type
  1. 4.1 AI Clinical Endpoint Assessment Software Type Introduction
  2. 4.1.1 Medical Imaging Endpoints
  3. 4.1.2 Digital Pathology Endpoints
  4. 4.1.3 Electronic Clinical Outcome Assessment
  5. 4.1.4 Wearable and Physiological Endpoints
  6. 4.1.5 Voice, Video and Cognitive Endpoints
  7. 4.1.6 Multimodal Endpoints
  8. 4.2 Global AI Clinical Endpoint Assessment Software Sales Value by Type
  9. 4.2.1 Global AI Clinical Endpoint Assessment Software Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global AI Clinical Endpoint Assessment Software Sales Value by Type (2021-2032)
  11. 4.2.3 Global AI Clinical Endpoint Assessment Software Sales Value Share by Type (2021-2032)
5 AI Clinical Endpoint Assessment Software Market by Application
  1. 5.1 AI Clinical Endpoint Assessment Software Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Neurology and Psychiatry
  4. 5.1.3 Cardiovascular and Metabolic Diseases
  5. 5.1.4 Respiratory Diseases
  6. 5.1.5 Musculoskeletal and Immunology
  7. 5.1.6 Other Therapeutic Areas
  8. 5.2 Global AI Clinical Endpoint Assessment Software Sales Value by Application
  9. 5.2.1 Global AI Clinical Endpoint Assessment Software Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global AI Clinical Endpoint Assessment Software Sales Value by Application (2021-2032)
  11. 5.2.3 Global AI Clinical Endpoint Assessment Software Sales Value Share by Application (2021-2032)
6 AI Clinical Endpoint Assessment Software Regional Value Analysis
  1. 6.1 Global AI Clinical Endpoint Assessment Software Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global AI Clinical Endpoint Assessment Software Sales Value by Region (2021-2032)
  3. 6.2.1 Global AI Clinical Endpoint Assessment Software Sales Value by Region: 2021-2026
  4. 6.2.2 Global AI Clinical Endpoint Assessment Software Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America AI Clinical Endpoint Assessment Software Sales Value (2021-2032)
  7. 6.3.2 North America AI Clinical Endpoint Assessment Software Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe AI Clinical Endpoint Assessment Software Sales Value (2021-2032)
  10. 6.4.2 Europe AI Clinical Endpoint Assessment Software Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific AI Clinical Endpoint Assessment Software Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific AI Clinical Endpoint Assessment Software Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America AI Clinical Endpoint Assessment Software Sales Value (2021-2032)
  16. 6.6.2 South America AI Clinical Endpoint Assessment Software Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa AI Clinical Endpoint Assessment Software Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa AI Clinical Endpoint Assessment Software Sales Value Share by Country, 2025 VS 2032
7 AI Clinical Endpoint Assessment Software Country-level Value Analysis
  1. 7.1 Global AI Clinical Endpoint Assessment Software Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global AI Clinical Endpoint Assessment Software Sales Value by Country (2021-2032)
  3. 7.2.1 Global AI Clinical Endpoint Assessment Software Sales Value by Country (2021-2026)
  4. 7.2.2 Global AI Clinical Endpoint Assessment Software Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt AI Clinical Endpoint Assessment Software Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt AI Clinical Endpoint Assessment Software Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt AI Clinical Endpoint Assessment Software Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 IQVIA
  2. 8.1.1 IQVIA Company Information
  3. 8.1.2 IQVIA Business Overview
  4. 8.1.3 IQVIA AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  5. 8.1.4 IQVIA AI Clinical Endpoint Assessment Software Product Portfolio
  6. 8.1.5 IQVIA Recent Developments
  7. 8.2 ICON
  8. 8.2.1 ICON Company Information
  9. 8.2.2 ICON Business Overview
  10. 8.2.3 ICON AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  11. 8.2.4 ICON AI Clinical Endpoint Assessment Software Product Portfolio
  12. 8.2.5 ICON Recent Developments
  13. 8.3 Perceptive
  14. 8.3.1 Perceptive Company Information
  15. 8.3.2 Perceptive Business Overview
  16. 8.3.3 Perceptive AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Perceptive AI Clinical Endpoint Assessment Software Product Portfolio
  18. 8.3.5 Perceptive Recent Developments
  19. 8.4 Clinical Ink
  20. 8.4.1 Clinical Ink Company Information
  21. 8.4.2 Clinical Ink Business Overview
  22. 8.4.3 Clinical Ink AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Clinical Ink AI Clinical Endpoint Assessment Software Product Portfolio
  24. 8.4.5 Clinical Ink Recent Developments
  25. 8.5 Koneksa
  26. 8.5.1 Koneksa Company Information
  27. 8.5.2 Koneksa Business Overview
  28. 8.5.3 Koneksa AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Koneksa AI Clinical Endpoint Assessment Software Product Portfolio
  30. 8.5.5 Koneksa Recent Developments
  31. 8.6 AiCure
  32. 8.6.1 AiCure Company Information
  33. 8.6.2 AiCure Business Overview
  34. 8.6.3 AiCure AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AiCure AI Clinical Endpoint Assessment Software Product Portfolio
  36. 8.6.5 AiCure Recent Developments
  37. 8.7 Medable
  38. 8.7.1 Medable Company Information
  39. 8.7.2 Medable Business Overview
  40. 8.7.3 Medable AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Medable AI Clinical Endpoint Assessment Software Product Portfolio
  42. 8.7.5 Medable Recent Developments
  43. 8.8 PathAI
  44. 8.8.1 PathAI Company Information
  45. 8.8.2 PathAI Business Overview
  46. 8.8.3 PathAI AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  47. 8.8.4 PathAI AI Clinical Endpoint Assessment Software Product Portfolio
  48. 8.8.5 PathAI Recent Developments
  49. 8.9 Proscia
  50. 8.9.1 Proscia Company Information
  51. 8.9.2 Proscia Business Overview
  52. 8.9.3 Proscia AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Proscia AI Clinical Endpoint Assessment Software Product Portfolio
  54. 8.9.5 Proscia Recent Developments
  55. 8.10 Paige
  56. 8.10.1 Paige Company Information
  57. 8.10.2 Paige Business Overview
  58. 8.10.3 Paige AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Paige AI Clinical Endpoint Assessment Software Product Portfolio
  60. 8.10.5 Paige Recent Developments
  61. 8.11 IXICO
  62. 8.11.1 IXICO Company Information
  63. 8.11.2 IXICO Business Overview
  64. 8.11.3 IXICO AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  65. 8.11.4 IXICO AI Clinical Endpoint Assessment Software Product Portfolio
  66. 8.11.5 IXICO Recent Developments
  67. 8.12 Median Technologies
  68. 8.12.1 Median Technologies Company Information
  69. 8.12.2 Median Technologies Business Overview
  70. 8.12.3 Median Technologies AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Median Technologies AI Clinical Endpoint Assessment Software Product Portfolio
  72. 8.12.5 Median Technologies Recent Developments
  73. 8.13 VIDA Diagnostics
  74. 8.13.1 VIDA Diagnostics Company Information
  75. 8.13.2 VIDA Diagnostics Business Overview
  76. 8.13.3 VIDA Diagnostics AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  77. 8.13.4 VIDA Diagnostics AI Clinical Endpoint Assessment Software Product Portfolio
  78. 8.13.5 VIDA Diagnostics Recent Developments
  79. 8.14 Image Analysis Group
  80. 8.14.1 Image Analysis Group Company Information
  81. 8.14.2 Image Analysis Group Business Overview
  82. 8.14.3 Image Analysis Group AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Image Analysis Group AI Clinical Endpoint Assessment Software Product Portfolio
  84. 8.14.5 Image Analysis Group Recent Developments
  85. 8.15 QMENTA
  86. 8.15.1 QMENTA Company Information
  87. 8.15.2 QMENTA Business Overview
  88. 8.15.3 QMENTA AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  89. 8.15.4 QMENTA AI Clinical Endpoint Assessment Software Product Portfolio
  90. 8.15.5 QMENTA Recent Developments
  91. 8.16 Cambridge Cognition
  92. 8.16.1 Cambridge Cognition Company Information
  93. 8.16.2 Cambridge Cognition Business Overview
  94. 8.16.3 Cambridge Cognition AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Cambridge Cognition AI Clinical Endpoint Assessment Software Product Portfolio
  96. 8.16.5 Cambridge Cognition Recent Developments
  97. 8.17 Cogstate
  98. 8.17.1 Cogstate Company Information
  99. 8.17.2 Cogstate Business Overview
  100. 8.17.3 Cogstate AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Cogstate AI Clinical Endpoint Assessment Software Product Portfolio
  102. 8.17.5 Cogstate Recent Developments
  103. 8.18 Empatica
  104. 8.18.1 Empatica Company Information
  105. 8.18.2 Empatica Business Overview
  106. 8.18.3 Empatica AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Empatica AI Clinical Endpoint Assessment Software Product Portfolio
  108. 8.18.5 Empatica Recent Developments
  109. 8.19 Cumulus Neuroscience
  110. 8.19.1 Cumulus Neuroscience Company Information
  111. 8.19.2 Cumulus Neuroscience Business Overview
  112. 8.19.3 Cumulus Neuroscience AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Cumulus Neuroscience AI Clinical Endpoint Assessment Software Product Portfolio
  114. 8.19.5 Cumulus Neuroscience Recent Developments
  115. 8.20 Rune Labs
  116. 8.20.1 Rune Labs Company Information
  117. 8.20.2 Rune Labs Business Overview
  118. 8.20.3 Rune Labs AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Rune Labs AI Clinical Endpoint Assessment Software Product Portfolio
  120. 8.20.5 Rune Labs Recent Developments
  121. 8.21 VivoSense
  122. 8.21.1 VivoSense Company Information
  123. 8.21.2 VivoSense Business Overview
  124. 8.21.3 VivoSense AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  125. 8.21.4 VivoSense AI Clinical Endpoint Assessment Software Product Portfolio
  126. 8.21.5 VivoSense Recent Developments
  127. 8.22 NeuraLight
  128. 8.22.1 NeuraLight Company Information
  129. 8.22.2 NeuraLight Business Overview
  130. 8.22.3 NeuraLight AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  131. 8.22.4 NeuraLight AI Clinical Endpoint Assessment Software Product Portfolio
  132. 8.22.5 NeuraLight Recent Developments
  133. 8.23 Aural Analytics
  134. 8.23.1 Aural Analytics Company Information
  135. 8.23.2 Aural Analytics Business Overview
  136. 8.23.3 Aural Analytics AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Aural Analytics AI Clinical Endpoint Assessment Software Product Portfolio
  138. 8.23.5 Aural Analytics Recent Developments
  139. 8.24 Linus Health
  140. 8.24.1 Linus Health Company Information
  141. 8.24.2 Linus Health Business Overview
  142. 8.24.3 Linus Health AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Linus Health AI Clinical Endpoint Assessment Software Product Portfolio
  144. 8.24.5 Linus Health Recent Developments
  145. 8.25 Quibim
  146. 8.25.1 Quibim Company Information
  147. 8.25.2 Quibim Business Overview
  148. 8.25.3 Quibim AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Quibim AI Clinical Endpoint Assessment Software Product Portfolio
  150. 8.25.5 Quibim Recent Developments
  151. 8.26 Perspectum
  152. 8.26.1 Perspectum Company Information
  153. 8.26.2 Perspectum Business Overview
  154. 8.26.3 Perspectum AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Perspectum AI Clinical Endpoint Assessment Software Product Portfolio
  156. 8.26.5 Perspectum Recent Developments
  157. 8.27 Brainomix
  158. 8.27.1 Brainomix Company Information
  159. 8.27.2 Brainomix Business Overview
  160. 8.27.3 Brainomix AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  161. 8.27.4 Brainomix AI Clinical Endpoint Assessment Software Product Portfolio
  162. 8.27.5 Brainomix Recent Developments
  163. 8.28 Taimei Technology
  164. 8.28.1 Taimei Technology Company Information
  165. 8.28.2 Taimei Technology Business Overview
  166. 8.28.3 Taimei Technology AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  167. 8.28.4 Taimei Technology AI Clinical Endpoint Assessment Software Product Portfolio
  168. 8.28.5 Taimei Technology Recent Developments
  169. 8.29 UnionClin
  170. 8.29.1 UnionClin Company Information
  171. 8.29.2 UnionClin Business Overview
  172. 8.29.3 UnionClin AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  173. 8.29.4 UnionClin AI Clinical Endpoint Assessment Software Product Portfolio
  174. 8.29.5 UnionClin Recent Developments
  175. 8.30 XincereMed
  176. 8.30.1 XincereMed Company Information
  177. 8.30.2 XincereMed Business Overview
  178. 8.30.3 XincereMed AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  179. 8.30.4 XincereMed AI Clinical Endpoint Assessment Software Product Portfolio
  180. 8.30.5 XincereMed Recent Developments
  181. 8.31 Clario
  182. 8.31.1 Clario Company Information
  183. 8.31.2 Clario Business Overview
  184. 8.31.3 Clario AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  185. 8.31.4 Clario AI Clinical Endpoint Assessment Software Product Portfolio
  186. 8.31.5 Clario Recent Developments
  187. 8.32 Medidata
  188. 8.32.1 Medidata Company Information
  189. 8.32.2 Medidata Business Overview
  190. 8.32.3 Medidata AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  191. 8.32.4 Medidata AI Clinical Endpoint Assessment Software Product Portfolio
  192. 8.32.5 Medidata Recent Developments
  193. 8.33 Signant Health
  194. 8.33.1 Signant Health Company Information
  195. 8.33.2 Signant Health Business Overview
  196. 8.33.3 Signant Health AI Clinical Endpoint Assessment Software Revenue and Gross Margin (2021-2026)
  197. 8.33.4 Signant Health AI Clinical Endpoint Assessment Software Product Portfolio
  198. 8.33.5 Signant Health Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst